Global Cord Blood Corporation (NYSE: CO) is a leading operator of umbilical cord blood banking services in the People’s Republic of China. The company provides critical stem cell preservation and related services through its network of cord blood banks and medical partners. Its core activities encompass the collection, processing, testing, and long-term storage of cord blood units, which are preserved for potential therapeutic use in the treatment of hematological and genetic disorders.
In addition to cord blood banking, Global Cord Blood offers supplemental clinical services such as viability testing, stem cell expansion research, and personalized consultation for expectant parents. The company serves both private clients seeking to secure their child’s cord blood for family use and public donors interested in contributing to broader medical research and public health initiatives. Through collaborations with maternity hospitals and obstetric clinics, Global Cord Blood ensures standardized collection protocols and quality control across its facilities.
Founded in 2004 and incorporated in the Cayman Islands, Global Cord Blood has expanded its footprint to cover more than 30 major cities across China. The company’s public listing on the New York Stock Exchange in November 2015 marked a significant milestone in its growth trajectory, providing capital to enhance its processing capabilities and expand its regional laboratories. Headquartered in Guangzhou, Global Cord Blood maintains a network of accredited labs in key provinces, including Guangdong, Shandong, and Beijing, supporting both domestic banking and research partnerships.
Led by a management team with extensive experience in biotechnology, healthcare operations, and regulatory compliance, Global Cord Blood continues to pursue strategic alliances with research institutions and clinical centers. The company’s ongoing efforts to advance stem cell technologies and expand its nationwide collection network aim to strengthen its position as a trusted provider of cord blood banking services in China’s emerging regenerative medicine market.
AI Generated. May Contain Errors.
Free CO Stock Alerts